# Ari Nowacek
Ari Nowacek, M.D., Ph.D., is an American life-science venture capitalist and a Partner at [ARCH Venture Partners](https://www.edgepedia.org/arch-venture-partners). He joined ARCH as an Analyst in March 2015 and was promoted to Partner in June 2022, one of the firm's home-grown investors who rose from the entry level.[1](https://www.archventure.com/team/ari-nowacek/) • [2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html) He is also a co-founder of City Therapeutics, where he serves as Senior Vice President of Corporate Development.[1](https://www.archventure.com/team/ari-nowacek/)
| Fact | Detail |
|---|---|
| Firm and role | Partner at ARCH Venture Partners; joined as Analyst in March 2015[1](https://www.archventure.com/team/ari-nowacek/) |
| Promotion | Named Partner on June 7, 2022[2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html) |
| Education | B.S. Biology and B.S. Psychology, Indiana University-Bloomington; M.D. and Ph.D., University of Nebraska Medical Center; M.B.A., University of Nebraska-Omaha[1](https://www.archventure.com/team/ari-nowacek/) |
| Research record | Over 25 peer-reviewed publications and seven issued patents as of June 2022[2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html) |
| Companies co-founded | HiberCell, Walden Biosciences, ROME Therapeutics, City Therapeutics[1](https://www.archventure.com/team/ari-nowacek/) • [2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html) |
| Board roles | Board member of HiberCell and Walden Biosciences[2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html); Director of Basking Biosciences Inc and Synchron Inc per SEC Form D filings[3](https://aum13f.com/person/ari-nowacek) |
| Other companies he helped build | Arbor Biotechnologies, Ultivue, Basking Bio, Synchron[1](https://www.archventure.com/team/ari-nowacek/) • [2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html) |
## Education and early scientific career
Nowacek trained as a physician-scientist before entering venture capital. He earned a B.S. in Biology and a B.S. in [Psychology](https://www.edgepedia.org/psychology) from [Indiana University](https://www.edgepedia.org/indiana-university)-Bloomington, then an M.D. and Ph.D. from the [University of Nebraska Medical Center](https://www.edgepedia.org/university-of-nebraska-medical-center) and an M.B.A. from the University of Nebraska-Omaha.[1](https://www.archventure.com/team/ari-nowacek/)
He completed a pathology residency and postdoctoral research at The University of Chicago and [Massachusetts General Hospital](https://www.edgepedia.org/massachusetts-general-hospital).[1](https://www.archventure.com/team/ari-nowacek/) His published research spans oncology, neuroscience, virology, and antiretroviral therapeutic development; by June 2022 he had more than 25 peer-reviewed publications and over 400 citations, and his research had led to seven issued patents for therapeutic and R&D applications.[2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html)
## Career at ARCH Venture Partners
Nowacek joined ARCH Venture Partners as an Analyst in March 2015.[1](https://www.archventure.com/team/ari-nowacek/) On June 7, 2022, ARCH announced his promotion to Partner, in the same announcement that elevated Sean Kendall to Partner, Europe, and [Corey Ritter](https://www.edgepedia.org/corey-ritter) and Nilay Thakar to Principal.[2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html) ARCH co-founder [Keith Crandell](https://www.edgepedia.org/keith-crandell) noted that all of the promoted investors had started at the firm at the Associate or Analyst level, placing Nowacek in the firm's practice of developing investors internally.[2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html)
His role at the firm, as the firm's profile describes it, is to identify and evaluate new life sciences technologies and to provide operating assistance to early-stage portfolio companies.[1](https://www.archventure.com/team/ari-nowacek/)
## Notable investments and company creation
Nowacek's record centers on company creation rather than later-stage checks. The 2022 promotion release names him as a co-founder of HiberCell, Walden Biosciences and ROME Therapeutics, and credits him with instrumental roles in developing Ultivue and [Arbor Biotechnologies](https://www.edgepedia.org/arbor-biotechnologies).[2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html) His firm biography adds Basking Bio and Synchron to the list of ARCH companies he helped develop.[1](https://www.archventure.com/team/ari-nowacek/)
He is a co-founder of City Therapeutics and serves there as Senior Vice President of Corporate Development.[1](https://www.archventure.com/team/ari-nowacek/)
SEC Form D filings add financing detail for two of his directorships. Basking Biosciences Inc (Form D 021-497367) raised $55.0 million of a $55.0 million offering, and Synchron Inc (Form D 021-467979) raised $49.9 million of an $86.0 million offering.[3](https://aum13f.com/person/ari-nowacek)
## Boards and public positions
As of June 2022, Nowacek served as a board member for HiberCell and Walden Biosciences and as a board observer for Arbor Biotechnologies, ROME Therapeutics, and Ultivue.[2](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html) SEC Form D filings additionally list him as a Director of Basking Biosciences Inc and of Synchron Inc.[3](https://aum13f.com/person/ari-nowacek)
## What the sources do not settle
No source reviewed here reports exit outcomes or valuations for his investments, including Arbor Biotechnologies; no source reports any controversies, disputes, or regulatory matters involving him; and no source quotes his own statements on investment themes such as AI-driven drug discovery or genetic medicines. Round types, dates, and amounts for his involvement in Arbor Biotechnologies, HiberCell, and Synchron beyond the Form D figures above are likewise not documented in the sources used for this article.
## References
1. [Ari Nowacek, M.D, Ph.D. - ARCH Venture Partners](https://www.archventure.com/team/ari-nowacek/)
2. [ARCH Venture Partners Announces Promotions and New Appointment (PR Newswire, June 7, 2022)](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-promotions-and-new-appointment-301561845.html)
3. [Ari Nowacek | AUM 13F (SEC Form D data)](https://aum13f.com/person/ari-nowacek)
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Biotech venture capital partners › Titles A to J*
*Initially written Sep 17, 2026 · Edited: Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license